| Cancer immunotherapy trial design with cure rate and delayed treatment effect J Wei, J Wu Statistics in medicine 39 (6), 698-708, 2020 | 15 | 2020 |
| Impact of patient load on the quality of electronic medical record documentation A Jacob, R Raj, S Alagusundaramoorthy, J Wei, J Wu, M Eng Journal of medical education and curricular development 8, 2382120520988597, 2021 | 8 | 2021 |
| Two‐stage phase II survival trial design J Wu, L Chen, J Wei, H Weiss, A Chauhan Pharmaceutical Statistics 19 (3), 214-229, 2020 | 7 | 2020 |
| Phase II trial design with growth modulation index as the primary endpoint J Wu, L Chen, J Wei, H Weiss, RW Miller, JL Villano Pharmaceutical statistics 18 (2), 212-222, 2019 | 6 | 2019 |
| Cancer immunotherapy trial design with delayed treatment effect J Wu, J Wei Pharmaceutical Statistics 19 (3), 202-213, 2020 | 5 | 2020 |
| Cancer immunotherapy trial design with random delayed treatment effect and cure rate J Wu, J Wei Statistics in Medicine 41 (4), 786-797, 2022 | 3 | 2022 |
| Prognostic and predictive factors associated with ipilimumab-related adverse events: a retrospective analysis of 11 NCI-sponsored phase I clinical trials A Chauhan, T Kabir, J Wu, J Wei, M Cook, CA Kunos Oncotarget 11 (16), 1427, 2020 | | 2020 |
| Prognostic and predictive factors associated with ipilimumab related adverse events: A retrospective analysis of 11 NCI sponsored ipilimumab phase I clinical trials. A Chauhan, T Kabir, J Wu, J Wei, C Kunos Journal of Clinical Oncology 37 (8_suppl), 86-86, 2019 | | 2019 |
